Business context and reporting period
BeiGene, Ltd. is a global commercial-stage biotechnology company developing and selling cancer medicines. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2021; financial figures below are in U.S. dollars and generally stated in millions.
Its marketed products include internally developed BRUKINSA, tislelizumab and pamiparib, alongside medicines licensed from Amgen, BMS and other partners. In January 2021, BeiGene licensed tislelizumab rights in North America, Europe and Japan to Novartis.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Total revenue | $206.4 | $91.1 | $962.3 | $208.8 |
| Net product revenue | $192.5 | $91.1 | $437.2 | $208.8 |
| Collaboration revenue | $14.0 | — | $525.1 | — |
| Loss from operations | $(462.3) | $(440.1) | $(867.0) | $(1,172.8) |
| Net loss attributable to BeiGene | $(413.9) | $(425.2) | $(827.7) | $(1,124.2) |
| Operating cash flow | Not separately presented for the quarter | $(790.9) | $(951.1) |
Product gross margin was $145.0 million, or 75.4% of product sales, in Q3, compared with $70.0 million, or 76.8%, a year earlier. For the nine-month period, gross margin was $320.8 million, or 73.4%, versus $159.2 million, or 76.3%. The filing attributes the margin decline mainly to lower NRDL prices and related distributor compensation, partly offset by a higher BRUKINSA sales mix.
As of September 30, cash, cash equivalents and restricted cash were $1,389.7 million and short-term investments were $2,533.6 million. Total debt was $643.3 million, comprising $442.4 million of short-term debt and $200.9 million of long-term bank loans. Cash, cash equivalents and restricted cash were nearly unchanged from year-end 2020; short-term investments fell from $3,268.7 million. Nine-month capital expenditures were $148.0 million. The filing says existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital expenditures for at least 12 months after issuance of the statements.
Product sales rose 111.3% in Q3 and 109.4% over nine months year over year. Q3 growth was led by BRUKINSA ($65.8 million), tislelizumab ($77.0 million) and XGEVA ($15.7 million). Nine-month collaboration revenue included $484.6 million recognized on delivery of the Novartis license and $40.5 million for R&D services. Q3 other income included a $23.8 million unrealized gain on the Leap Therapeutics investment.
Material changes, outlook and risks
- Costs and losses: Nine-month R&D expense increased 9.5% to $1,028.8 million, while selling, general and administrative expense rose 74.4% to $683.6 million, reflecting expansion of development and commercial operations. The nine-month net loss narrowed year over year, but Q3 operating loss widened.
- Cash use and funding: Operating activities used $790.9 million in the first nine months. Management expects continued losses and says future funding needs depend on development, approvals, manufacturing and commercialization. No specific revenue or earnings guidance is provided.
- Commitments: Remaining Amgen co-development funding was $851.1 million. Other disclosed obligations included $268.5 million of purchase commitments, $74.4 million of R&D commitments and $57.7 million of capital commitments.
- ABRAXANE dispute: China’s regulator suspended ABRAXANE imports, sales and use in 2020, and the product generated no revenue in the first nine months of 2021. BMS-Celgene gave notice in October 2021 that it purported to terminate the license and withdraw the product. BeiGene disputes the notice and is pursuing arbitration; BMS-Celgene counterclaimed for approximately $17 million, and a hearing was scheduled for June 2022.
- Commercial and regulatory uncertainty: NRDL inclusion supported demand for certain products but brought price reductions and distributor compensation. Competition, reimbursement and pricing, trial outcomes, regulatory approvals, third-party manufacturing and COVID-19 remain risks.
- Liquidity and operating risks: The filing identifies substantial continuing cash burn, short-term debt maturities, foreign-exchange and PRC currency-transfer restrictions, and risks from China-U.S. relations and limits on PCAOB inspection of the auditor.
Important facts for investors to verify
- How much of reported nine-month revenue growth reflects recurring product sales versus the one-time $484.6 million Novartis license revenue.
- Whether product growth and reimbursement-driven demand can offset NRDL price reductions, rebates and rising commercial costs.
- Resolution and financial consequences of the ABRAXANE suspension, purported termination and arbitration, including the counterclaim.
- Debt extensions, repayments and refinancing after quarter-end, particularly for loans classified as short-term at September 30, 2021.
- Actual cash burn, capital spending and funding needs relative to management’s stated minimum 12-month liquidity outlook and the disclosed collaboration commitments.
- Progress and approvals for key clinical programs, manufacturing capacity, and the proposed STAR Market offering, which remained subject to additional approvals and market conditions.